Literature DB >> 19411172

Therapy for neuromuscular disorders.

Andrea L H Arnett1, Joel R Chamberlain, Jeffrey S Chamberlain.   

Abstract

Research into therapeutic approaches for both recessive and dominant neuromuscular disorders has made great progress over the past few years. In the field of gene therapy, antisense-mediated exon skipping is being applied to bypass deleterious mutations in the dystrophin gene and restore dystrophin expression in animal models of muscular dystrophy. Approaches for the dominant genetic muscle diseases have turned toward elimination of the mutant gene product with anti-sense oligonucleotide therapy and RNA interference techniques. Refinements of adeno-associated viral vectors and strategies for their delivery are also leading towards future clinical trials. The discovery of new, multipotent cell lineages, some of which possess the ability to successfully engraft muscle following vascular delivery, presents exciting prospects for the field of stem cell therapy. These discoveries represent steady progress towards the development of effective therapies for a wide range of neuromuscular disorders.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19411172     DOI: 10.1016/j.gde.2009.03.005

Source DB:  PubMed          Journal:  Curr Opin Genet Dev        ISSN: 0959-437X            Impact factor:   5.578


  9 in total

Review 1.  Animal models of muscular dystrophy.

Authors:  Rainer Ng; Glen B Banks; John K Hall; Lindsey A Muir; Julian N Ramos; Jacqueline Wicki; Guy L Odom; Patryk Konieczny; Jane Seto; Joel R Chamberlain; Jeffrey S Chamberlain
Journal:  Prog Mol Biol Transl Sci       Date:  2012       Impact factor: 3.622

Review 2.  Gene replacement therapies for duchenne muscular dystrophy using adeno-associated viral vectors.

Authors:  Jane T Seto; Julian N Ramos; Lindsey Muir; Jeffrey S Chamberlain; Guy L Odom
Journal:  Curr Gene Ther       Date:  2012-06       Impact factor: 4.391

3.  Muscling in: Gene therapies for muscular dystrophy target RNA.

Authors:  Joel R Chamberlain; Jeffrey S Chamberlain
Journal:  Nat Med       Date:  2010-02       Impact factor: 53.440

4.  A First Step in Viral Gene Therapy for Muscular Dystrophy.

Authors:  Michio Hirano
Journal:  Curr Neurol Neurosci Rep       Date:  2010-03       Impact factor: 5.081

5.  The genetic basis of non-syndromic intellectual disability: a review.

Authors:  Liana Kaufman; Muhammad Ayub; John B Vincent
Journal:  J Neurodev Disord       Date:  2010-07-29       Impact factor: 4.025

Review 6.  Progress in muscular dystrophy research with special emphasis on gene therapy.

Authors:  Hideo Sugita; Shin'ichi Takeda
Journal:  Proc Jpn Acad Ser B Phys Biol Sci       Date:  2010       Impact factor: 3.493

7.  Immune Responses to rAAV6: The Influence of Canine Parvovirus Vaccination and Neonatal Administration of Viral Vector.

Authors:  Andrea L H Arnett; Dilip Garikipati; Zejing Wang; Stephen Tapscott; Jeffrey S Chamberlain
Journal:  Front Microbiol       Date:  2011-11-03       Impact factor: 5.640

8.  Altered Tnnt3 characterizes selective weakness of fast fibers in mice overexpressing FSHD region gene 1 (FRG1).

Authors:  Valentina Sancisi; Elena Germinario; Alessandra Esposito; Elisabetta Morini; Samantha Peron; Maurizio Moggio; Giuliano Tomelleri; Daniela Danieli-Betto; Rossella Tupler
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2013-12-04       Impact factor: 3.619

Review 9.  At the Crossroads of Clinical and Preclinical Research for Muscular Dystrophy-Are We Closer to Effective Treatment for Patients?

Authors:  Kinga I Gawlik
Journal:  Int J Mol Sci       Date:  2018-05-16       Impact factor: 5.923

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.